Drug intelligence / Profile preview

microRNA-184 mimic

Development stage
Preclinical
Lead developer
부산대학교
Modality
RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intranasal
01

Overview

A microRNA mimic designed to restore or enhance the activity of miR-184. In the context of glioblastoma multiforme (GBM), miR-184 acts as a tumor suppressor by targeting SLC25A22, a mitochondrial glutamate transporter. Upregulation of SLC25A22 in radioresistant GBM cells leads to increased cytosolic glutamate, which fuels glutathione (GSH) and proline synthesis, promoting radioresistance and invasiveness. By mimicking miR-184, this agent downregulates SLC25A22, thereby remodeling glutamate metabolism, reducing antioxidant capacity, and sensitizing GBM cells to radiotherapy. Preclinical studies have demonstrated that intranasal administration can prolong survival in GBM-bearing mice.

Other names
miR-184 mimicmiR184 mimicmiR 184 mimichsa-miR-184 mimichsa-miR184 mimichsa-miR 184 mimic
02

Targets

MYC (MYC proto-oncogene protein)Solute carrier family 25 member 22 mRNA 3′-untranslated region (SLC25A22 mRNA 3′-UTR)BCL-2 (BCL-2 family)AKT2 (Rac-beta serine/threonine-protein kinase)Tumor necrosis factor alpha-induced protein 2 mRNA 3′-untranslated region (TNFAIP2 mRNA 3′-UTR)

Beyond the preview

Go deeper on microRNA-184 mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on microRNA-184 mimic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call